Coldstream Capital Management Inc. Invests $205,000 in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Coldstream Capital Management Inc. purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,783 shares of the company’s stock, valued at approximately $205,000.

Other hedge funds have also added to or reduced their stakes in the company. Quest Partners LLC increased its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares during the period. nVerses Capital LLC grew its stake in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank raised its holdings in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after acquiring an additional 181 shares during the period. Finally, Blue Trust Inc. lifted its position in Prestige Consumer Healthcare by 106.9% during the second quarter. Blue Trust Inc. now owns 867 shares of the company’s stock worth $63,000 after acquiring an additional 448 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. This represents a 33.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last three months. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Down 2.0 %

PBH opened at $80.39 on Wednesday. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 19.56, a P/E/G ratio of 2.32 and a beta of 0.49. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a twelve month low of $57.95 and a twelve month high of $86.36. The company has a 50-day simple moving average of $78.65 and a 200 day simple moving average of $72.86.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.07 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on PBH. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.